SML3353
GSK943
≥98% (HPLC)
别名:
(2R,3R)-N5-((1R,5S,6r)-3-oxabicyclo[3.1.0]hexan-6-yl)-2-(fluoromethyl)-N7-methyl-3-phenyl-2,3-dihydrobenzofuran-5,7-dicarboxamide
InChI key
WZQLVEPIBAOOGF-PXTPFGJHSA-N
SMILES string
CNC(C1=C2C([C@](C3=CC=CC=C3)([H])[C@@H](O2)CF)=CC(C(N[C@@H]4[C@]5([H])[C@@]4([H])COC5)=O)=C1)=O
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
Quality Level
Biochem/physiol Actions
Inactive (2R,3R) stereoisomer of and the recommended negative control for the potent and selective pan-second bromodomain (BD2) inhibitor GSK973.
GSK943 corresponds to the inactive (2R,3R) stereoisomer of and the recommended negative control for the potent and selective pan-second bromodomain (BD2) inhibitor GSK973.
GSK943 corresponds to the inactive (2R,3R) stereoisomer of and the recommended negative control for the potent and selective pan-second bromodomain (BD2) inhibitor GSK973.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Alex Preston et al.
ACS medicinal chemistry letters, 11(8), 1581-1587 (2020-08-25)
Pan-BET inhibitors have shown profound efficacy in a number of in vivo preclinical models and have entered the clinic in oncology trials where adverse events have been reported. These inhibitors interact equipotently with the eight bromodomains of the BET family
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持